07 Feb Atamyo Therapeutics
Posted at 21:03h
in
Stephane Degove, CEO
Evry, France
(Private)
Atamyo Therapeutics is a clinical-stage biopharma focused on the development of a new generation of effective and safe gene therapies for neuromuscular diseases. A spin-off of gene therapy pioneer Genethon, Atamyo leverages unique expertise in AAV-based gene therapy and muscular dystrophies from the Progressive Muscular Dystrophies Laboratory at Genethon. Atamyo’s most advanced programs address different forms of limb-girdle muscular dystrophies (LGMD), with two clinical-stage programs targeting respectively LGMD-R9 and LGMD-R5. Initial positive clinical results with ATA-100 gene therapy in LGMD-R9 were presented in October 2024. Additional programs target LGMD-R1 and cardiomyopathies.
